

**Amendment Y
for Partner Project Agreement P-004**

This Amendment Y is entered into as of the 1st day of July 2022 by and between the Science and Technology Center in Ukraine (Center), the Institute of Endocrinology and Metabolism Academy of Medical Science of Ukraine (Recipient), and the National Cancer Institute of the United States of America (Partner).

This Amendment Y amends the Partner Project Agreement P-004 (Agreement), which commenced on January 1, 1998, together with Partner Project Agreement P-004A, which commenced on July 1, 1998, Partner Project Agreement P-004AA, which commenced on July 1, 1999, with Amendment for Partner Project Agreement P-004, which commenced on October 1, 1999, and Partner Project Agreement P-004B, which commenced on July 1, 2000, with Amendment C for Partner Project Agreement P-004, which commenced on April 1, 2001; with Amendment D for Partner Project Agreement P-004, which commenced on April 1, 2002; with Amendment E for Partner Project Agreement P-004, which commenced on April 1, 2003; with Amendment E1 for Partner Project Agreement P-004, which commenced on May 26, 2003; with Amendment E2 for Partner Project Agreement P-004, which commenced on 24 February, 2004; with Amendment F for Partner Project Agreement P-004, which commenced on April 1, 2004; with Amendment G for Partner Project Agreement P-004, which commenced on April 1, 2005; with Amendment H for Partner Project Agreement P-004, which commenced on April 1, 2006; with Amendment I for Partner Project Agreement P-004, which commenced on April 1, 2007; with Agreement of variation for Partner Project Agreement P-004, which commenced on April 1, 2008; with Agreement of variation for Partner Project Agreement P-004, which commenced on July 1, 2008; with Agreement of variation for Partner Project Agreement P-004, which commenced on September 1, 2008; with Amendment J for Partner Project Agreement P-004, which commenced on December 1, 2008; with Amendment K for Partner Project Agreement P-004, which commenced on December 1, 2009; with Amendment L for Partner Project Agreement P-004, which commenced on December 1, 2010; with Agreement of variation For Partner Project Agreement P-004L, which commenced on February 1, 2011, and with Agreement of variation For Partner Project Agreement P-004L, which commenced on May 1, 2011; with Amendment M for Partner Project Agreement P-004, which commenced on December 1, 2011; with Agreement of variation For Partner Project Agreement P-004M, which commenced on December 1, 2012; with Agreement of variation 1 For Partner Project Agreement P-004M, which commenced on March 1, 2013; with Agreement of variation 2 For Partner Project Agreement P-004M, which commenced on June 1, 2013; and with Agreement of variation 3 For Partner Project Agreement P-004M, which commenced on September 1, 2013; with Amendment O for Partner Project Agreement P-004, which commenced on September 20, 2013; with Agreement of variation For Partner Project Agreement P-004O, which commenced on March 20, 2014; with Amendment P1 for Partner Project Agreement P-004, which commenced on June 6, 2014; with Agreement of variation For Partner Project Agreement P-004N, which commenced on January 1, 2015; with Agreement of variation For Partner Project Agreement P-004P, which commenced on May 1, 2015; with Amendment Q for Partner Project Agreement P-004, which commenced on August 1, 2015; with Agreement of variation For Partner Project Agreement P-004Q, which commenced on November 1, 2015; with Agreement of variation For Partner Project Agreement P-004N, which commenced on November 1, 2015; with Amendment R for Partner Project Agreement P-004, which commenced on May 1, 2016; with Amendment R1 for Partner Project Agreement P-004, which commenced on May 1, 2016; and with Amendment N1 for Partner Project Agreement P-004, which commenced on May 1, 2016; with Amendment S for Partner Project Agreement P-004, which commenced on May 1, 2017; with Amendment S1 for Partner Project Agreement P-004, which commenced on August 1, 2017; with Amendment S2 for Partner Project Agreement P-004, which commenced on November 1, 2017; with Amendment T for Partner Project Agreement P-004, which commenced on May 1, 2018; with Amendment T1 for Partner Project Agreement P-004, which commenced on May 1, 2018; with Amendment T2 for Partner Project Agreement P-004, which commenced on May 1, 2018; with Amendment U for Partner Project Agreement P-004, which commenced on September 16, 2018; with Amendment U1 for Partner Project Agreement P-004, which commenced on September 16, 2018; with Amendment U2 for Partner Project Agreement P-004, which commenced on September 16; with Amendment U3 for Partner Project Agreement P-004, which commenced on September 16, 2018; with Amendment V1 for Partner Project Agreement P-004, which commenced on May 1, 2019; with Amendment V2 for Partner Project Agreement P-004, which commenced on May 1, 2019; with Amendment V3 for Partner Project Agreement P-004, which commenced on May 1, 2019, with Amendment V4 for Partner Project Agreement P-004, which commenced on May 1, 2019; with Amendment W for Partner Project Agreement P-004, which commenced on May 1, 2020; with Amendment W1 for Partner Project Agreement P-004, which commenced on May 1, 2020; and with Amendment W2 for Partner Project Agreement P-004, which commenced on May 1, 2020; with Amendment X for Partner Project Agreement P-004, which commenced on May 1, 2021; with Amendment X1 for Partner Project Agreement P-004,

which commenced on May 1, 2021; and with Amendment X2 for Partner Project Agreement P-004, which commenced on May 1, 2021 as per Article 12 of the Agreement.

This Amendment Y prolongs the term of this Agreement until June 30, 2023.

The Partner has agreed to provide financial support for this Amendment Y.

Article 2 – Duration of the Project is hereby amended as follows:

The duration of the Project is increased by 12 months starting from July 1, 2022.

Article 3 – Financial contribution of the Partner through the Center is hereby amended as follows:


- 3.1 The total cost of the Project .
- 3.3 The amount of cost for equipment, materials and other direct costs .
- 3.4 The amount of grant payments directly to individual participants in the Project .
- 3.5 Overhead to the Recipient, represented by its director .
- 3.6 The Center will receive fee for its service.

Article 13 - Annexes is hereby amended as follows:

Annex P004Y-P-budgetEN - Work plan supplements previous Annexes and becomes an integral part of the Agreement.

IN WITNESS WHEREOF, the Center, the Partner, and the Recipient, by their authorized representatives, have executed this Amendment.

For the Center



Curtis Bjelajac

Date of signing July 14, 2022

Executive Director
Science and Technology Center in Ukraine
7a Metalistiv Street,
Kyiv 03057, Ukraine
Tel/Fax: +380(44) 490-7150/45

For the Partner

Elizabeth K. Digitally signed by
Elizabeth K. Cahoon -S
Date: 2022.07.13
15:22:26 +0400
Cahoon -S

Elizabeth Cahoon, PhD

Date of signing _____

Project Director
Radiation Epidemiology Branch
Division of Cancer Epidemiology and
Genetics
National Cancer Institute
9609 Medical Center Drive
Room 7E524 MSC 9778
Bethesda MD 20892-9778 (USPS only)
Phone: 240-276-7401
Fax: 240-276-7840

For the Recipient



Mykola Tronko, Academician

Date of signing _____

Project manager
Approved _____
Mykola Tronko, Academician
of the National Acad. Med. Sci. Ukraine
Director of the Institute of Endocrinology
and Metabolism, Academy of Medical
Sciences of Ukraine
Vyshgorodska Str. 69,
Kyiv 04114, Ukraine
Tel.: +380(44) 430 36 94
Fax: +380(44) 430 49 49